University of Massachusetts Chan Medical School | Medicine Department - Rheumatology Division

Research site

(Unclaimed)

Location

55 Lake Avenue North, Worcester, Massachusetts, United States of America

Site insights

Top conditions

Top treatments

Pembrolizumab

Guselkumab

HLX-0206

Ozanimod

LY2835219

NS-018

Betamethasone Valerate

Ustekinumab

Deucravacitinib

Luveltamab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

24 of 53 total trials

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo

Active, not recruiting

Stable Nonsegmental Vitiligo

Active Nonsegmental Vitiligo

Drug: Ritlecitinib

Drug: Placebo

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod...

Enrolling

Colitis, Ulcerative

Drug: Ozanimod

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse....

Active, not recruiting

Cytochrome P-450

Antineoplastic Agents, Hormonal

Drug: Placebo for Abemaciclib

Drug: Abemaciclib

A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with ultralow dose gemcitabine...

Enrolling

Endometrial Adenocarcinoma

Urothelial Carcinoma

Diagnostic Test: OncoSignature

Drug: ACR-368

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.

Enrolling

Epstein-Barr Virus Infection

Biological: Placebo

Biological: mRNA-1195.1

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refra...

Enrolling

Systemic Sclerosis

Idiopathic Inflammatory Myopathy

Drug: Fludarabine

Drug: CC-97540

A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN) (PROPEL)

This is a Phase 1/2 randomized, blinded, dose-escalation study to evaluate the safety and efficacy of intrathecal (IT) administration of SBT101, a re...

Enrolling

X-ALD

AMN Gene Mutation

Genetic: SBT101

Procedure: Imitation Procedure

A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies

The purpose of this study is to evaluate the effect of moderate or severe liver impairment on the drug levels of oral azacitidine and the safety and...

Enrolling

Neoplasms

Hepatic Insufficiency

Drug: Onureg

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2)

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe System...

Enrolling

Systemic Lupus Erythematosus

Drug: Deucravacitinib

Other: Placebo

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in t...

Enrolling

COVID-19 SARS-CoV-2 Infection

Drug: placebo

Drug: ibuzatrelvir

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide.There are 2 parts to this study...

Enrolling

Multiple Myeloma

Drug: Iberdomide

Drug: Elranatamab

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemipli...

Enrolling

Melanoma

Drug: Placebo

Drug: cemiplimab

An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15) (VALOR)

The main purpose of this clinical study is to evaluate a 6-valent OspA-based Lyme disease vaccine (VLA15) for prevention of Lyme disease within North...

Active, not recruiting

Lyme Disease

Biological: VLA15

Other: Saline

An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus (EMERALD)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). T...

Invitation-only

Systemic Lupus Erythematosus (SLE)

Drug: Litifilimab-matching placebo

Drug: Litifilimab

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and e...

Enrolling

COVID-19

Drug: nirmatrelvir

Drug: ritonavir

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients (EVOLUTION)

The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than swi...

Enrolling

Psoriatic Arthritis

Drug: Guselkumab

Drug: Golimumab

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

Researchers are looking for new ways to treat people with head and neck cancer whose cancer has come back after treatment (recurrent) or whose cancer...

Active, not recruiting

Squamous Cell Carcinoma of Head and Neck

Drug: Cetuximab

Drug: Capecitabine

MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels (MAGICAL SV)

This is a multicenter, randomized, single-blind pivotal study to evaluate the safety and efficacy of the MagicTouchTM Drug coated balloon in treatmen...

Enrolling

Coronary Artery Disease

Native Coronary Artery Stenosis

Device: Sirolimus Drug Coated Balloon

Device: Drug eluting stents (DES)

Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM (EF-32)

To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patient...

Active, not recruiting

Glioblastoma Multiforme

Device: Optune®

Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL) (OASIS)

This study will examine the safety and efficacy of TNX-102 SL to reduce ASR symptoms and behavioral changes among patients presenting to the emergenc...

Enrolling

Acute Stress Disorder

Neurocognitive Function

Drug: Placebo

Drug: Cyclobenzaprine HCl